Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Pemetrexed and Oxaliplatin in Locally Advanced HNSCC
NCT00503997Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Dec 2006
- Primary completion
- Jun 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemetrexed and oxaliplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Clinical Response Rate at 8 weeks. Started Dec 2006; status: completed.
02
Drugs
pemetrexedoxaliplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00503997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00503997.